Twist Bioscience (TWST) Cash from Financing Activities (2017 - 2026)

Twist Bioscience (TWST) has reported Cash from Financing Activities for 10 consecutive years, with $4.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 29.47% year-over-year to $4.1 million; the TTM figure through Mar 2026 stood at $11.8 million (down 57.23% YoY), while the FY2025 annual figure was $28.5 million, up 314.22% from the prior year.
• Cash from Financing Activities climbed to $4.1 million in Q1 2026 per TWST's latest filing, from $298000.0 in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $271.6 million in Q1 2022 and bottomed at -$1.5 million in Q4 2023.
• Historically, Cash from Financing Activities has averaged $18.4 million across 5 years, with a median of $1.8 million in 2025.
• Annual changes were most pronounced in 2022 — Cash from Financing Activities soared 18619.23% — and 2023, when it slumped 272.91%.
• Twist Bioscience's Cash from Financing Activities stood at -$395000.0 in 2022, then plunged by 272.91% to -$1.5 million in 2023, then jumped by 1318.19% to $17.9 million in 2024, then plunged by 98.34% to $298000.0 in 2025, then soared by 1288.59% to $4.1 million in 2026.
• Business Quant data shows TWST's Cash from Financing Activities at $4.1 million in Q1 2026, $298000.0 in Q4 2025, and $5.6 million in Q3 2025.